查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1938839

可萃取物和可浸出物測試服務市場 - 全球產業規模、佔有率、趨勢、機會及預測（按測試產品、技術、地區和競爭格局分類，2021-2031年）

Extractable & Leachable Testing Services Market - Global Industry Size, Share, Trends, Opportunity and Forecast, Segmented By Product Tested, By Technique, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球可萃取物和可浸出物測試服務市場預計將從 2025 年的 22.7 億美元成長到 2031 年的 47.6 億美元，複合年成長率為 13.13%。

這些服務專注於分析評估化學物質從容器密封系統、醫療設備和加工設施遷移到藥品的情況，以確保病患安全。該領域的成長主要得益於衛生監管機構對藥品與容器相互作用的嚴格監管，以及生物製藥日益成長的重要性——生物製劑對包裝材料尤為敏感。此外，對創新的大量資本投入也推動了該行業的擴張。例如，歐洲製藥工業協會聯合會 (EFPIA) 報告稱，到 2024 年，歐洲製藥業預計將投入 550 億歐元用於研發，並利用這些服務來檢驗新型治療方法。

市場概覽
預測期 2027-2031
市場規模：2025年 22.7億美元
市場規模：2031年 47.6億美元
複合年成長率：2026-2031年 13.13%
成長最快的細分市場 光譜測量
最大的市場 北美洲

然而，阻礙市場成長的一大障礙是缺乏全球統一的特定檢測通訊協定監管標準。不同地區的指導方針各異，給製造商帶來合規性挑戰，並常常導致重複檢測。這種缺乏統一性增加了營運成本，並延緩了藥品的國際商業化。

市場促進因素

生物製藥產業的快速成長及其生物製藥產品線是可萃取物和可萃取物檢測服務市場的主要驅動力。隨著該行業向複雜的大分子療法轉型，對容器密封系統進行嚴格的安全性評估對於防止產品污染至關重要。監管里程碑事件顯著體現了這波創新浪潮。美國食品藥物管理局(FDA) 於 2024 年 1 月發布的《透過創新促進健康：2023 年新藥療法核准》報告指出，共有 55 種新藥核准，所有這些藥物都需要進行全面的相容性測試。為了維持不斷擴大的產品線，製造商正在大力投資生產基礎設施，而這需要進行廣泛的驗證。例如，諾和諾德在 2024 年 6 月的新聞稿中宣布，將投資 41 億美元在北卡羅來納州新建一座填充和包裝工廠，這將直接推動對材料合格的需求。

同時，將分析測試外包給專業受託研究機構(CRO) 的策略性舉措正在顯著改變市場動態。製藥公司越來越依賴外部合作夥伴來利用高靈敏度的微量雜質檢測技術，從而避免了建造資本密集型內部實驗室的需求。這種外包模式使申辦方能夠專注於核心研發階段，同時有效率地應對合規方面的複雜問題。服務供應商的財務表現也印證了這種依賴性；Medpace Holdings, Inc. 在 2024 年 10 月發布的「2024 會計年度第三季」財報中公佈，其營收為 5.333 億美元，年成長 8.3%。 CRO 的持續成長凸顯了它們在開展全球產品商業化所需的關鍵安全性測試方面所發揮的重要作用。

市場挑戰

全球缺乏針對特定檢測通訊協定的統一監管標準，是限制萃取物及萃取物檢測服務市場效率及擴張的主要阻礙因素。不同司法管轄區的監管機構執行不同的安全準則，迫使製造商重複檢測以滿足每項獨特的要求。這種碎片化阻礙了實驗室評估方法的標準化，導致尋求國際分銷的製藥客戶面臨營運複雜性增加和成本上升的問題。

因此，這些監管上的不一致導致藥物核准時間延長，並延緩了治療藥物在全球市場的上市。這些合規障礙為整個藥物研發領域帶來了巨大的經濟負擔。據美國藥品研究與製造商協會（PhRMA）稱，其成員公司將在2024年投入約1030億美元用於研發，其中一部分巨額支出是由於需要應對複雜且不統一的監管安全評估。這種反覆檢驗的過程消耗了原本可以用於支援市場擴張的資源，從而阻礙了整個檢測服務產業的成長動能。

市場趨勢

對細胞和基因治療產品特性分析的日益重視，從根本上改變了萃取物及其檢測的技術要求。與傳統治療方法不同，這些先進治療方法通常使用病毒載體，並依賴複雜的單次使用裝置，因此對聚合物組分進行嚴格評估至關重要，以避免因萃取物引起的毒性和免疫抗原性。這種對材料安全性的日益重視與強大的產業資金投入直接相關。根據再生醫學聯盟於2025年1月發布的《產業趨勢簡報》，預計2024年，全球對細胞和基因治療領域的投資將達到152億美元。這筆巨額資金正在加速開發平臺，並迫使檢測實驗室實施專門的通訊協定，以檢測可能損害這些高價值生物製藥穩定性的微量萃取物。

同時，以患者為中心的自我給藥裝置的趨勢導致新型藥物輸送系統和組合產品的可萃取物和可浸出物檢測顯著增加。將藥物與預填充式注射器、自動注射器和穿戴式幫浦等醫療設備結合使用，需要進行全面的交互作用研究，因為橡膠活塞和矽油潤滑劑等新材料會與藥物直接接觸。輸送系統產量的成長也推動了這一趨勢。 2024年8月，肖特製藥在一份題為「肖特製藥第三季業績穩健」的新聞稿中宣布，其藥物傳輸系統部門的營收年增39%。器械製造的快速成長需要進行廣泛的可萃取物分析，以確保符合組合產品法規，從而維持對先進分析測試服務的需求。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶評價

5. 全球可萃取物和可浸出物檢測服務市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 受測目標產品（容器材料/包裝、一次性產品、醫療設備、生物製藥/生物製藥等）
    • 透過分析方法（光譜法、光譜法、總有機碳、電導率、其他）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

6. 北美可萃取物與可浸出物檢測服務市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國家分析
    • 美國
    • 加拿大
    • 墨西哥

7. 歐洲可萃取物和可浸出物檢測服務市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國家分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

8. 亞太地區可萃取物及可浸出物檢測服務市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

9. 中東和非洲可萃取物和可浸出物檢測服務市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東和非洲：國家分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

10. 南美洲可萃取物與可浸出物檢測服務市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國家分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進要素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 最新進展

第13章 全球可萃取物與可浸出物偵測服務市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的可能性
  • 供應商電力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Eurofins Scientific SE
  • SGS SA
  • Intertek Group plc
  • WuXi AppTec
  • Merck KGaA
  • West Pharmaceutical Services, Inc.
  • Boston Analytical
  • Medical Engineering Technologies Ltd.
  • Nelson Laboratories, LLC
  • Pace Analytical Services, LLC

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 9357

The Global Extractable & Leachable Testing Services Market is projected to expand from USD 2.27 Billion in 2025 to USD 4.76 Billion by 2031, registering a CAGR of 13.13%. These services focus on analytically assessing chemical migration from container closure systems, medical devices, and processing equipment into pharmaceutical products to guarantee patient safety. The sector is chiefly propelled by strict health authority regulations governing drug-container interactions and the increasing prominence of biologics, which are notably sensitive to packaging materials. Sector expansion is further bolstered by significant capital investment in innovation; for instance, the European Federation of Pharmaceutical Industries and Associations reported that the pharmaceutical industry allocated an estimated €55,000 million to research and development in Europe in 2024, leveraging these services to validate novel therapies.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 2.27 Billion
Market Size 2031USD 4.76 Billion
CAGR 2026-203113.13%
Fastest Growing SegmentSpectrometry
Largest MarketNorth America

However, a major obstacle hindering market growth is the absence of globally harmonized regulatory standards for specific testing protocols. Inconsistent guidelines across various geographic regions generate compliance difficulties for manufacturers, frequently requiring redundant testing procedures. This lack of uniformity elevates operational expenses and slows down the international commercialization of pharmaceutical products.

Market Driver

The rapid growth of the biopharmaceutical industry and its biologics pipeline serves as a major driver for the extractable and leachable testing services market. As the sector transitions toward complex large-molecule therapies, rigorous safety assessments of container closure systems are essential to prevent product contamination. This wave of innovation is highlighted by regulatory milestones; the U.S. Food and Drug Administration's "Advancing Health Through Innovation: New Drug Therapy Approvals 2023" report from January 2024 noted the approval of 55 novel drugs, all requiring thorough compatibility studies. To sustain these expansive pipelines, manufacturers are investing heavily in production infrastructure that necessitates extensive validation; for example, Novo Nordisk announced in a June 2024 press release a commitment of 4.1 billion USD to construct a new fill and finish facility in North Carolina, directly fueling the demand for material qualification.

Simultaneously, the strategic move toward outsourcing analytical testing to specialized Contract Research Organizations (CROs) is notably shaping market dynamics. Pharmaceutical firms are increasingly depending on external partners to utilize high-sensitivity trace impurity detection technologies, avoiding the need for capital-intensive internal laboratories. This outsourcing approach allows sponsors to manage compliance complexities efficiently while concentrating on core development stages. The financial performance of service providers illustrates this reliance; in its "Third Quarter 2024 Results" release from October 2024, Medpace Holdings, Inc. reported revenue of 533.3 million USD, an 8.3% year-over-year rise. Such consistent growth among CROs highlights their critical function in conducting mandatory safety testing for global product commercialization.

Market Challenge

The absence of global regulatory harmonization regarding specific testing protocols poses a major limitation on the efficiency and expansion of the Extractable and Leachable Testing Services Market. With regulatory bodies in different jurisdictions enforcing varying safety guidelines, manufacturers are forced to conduct duplicative testing to meet each unique requirement. This fragmentation hinders testing laboratories from standardizing their assessment methods, resulting in greater operational complexity and increased costs for pharmaceutical clients seeking international product distribution.

As a result, these regulatory inconsistencies extend drug approval timelines, delaying the global market entry of therapeutics. The financial toll of these compliance barriers is significant within the wider scope of drug development. According to the Pharmaceutical Research and Manufacturers of America, member companies invested roughly $103 billion in research and development in 2024, a vast expenditure driven in part by the need to manage complex and non-uniform regulatory safety assessments. This repetitive validation process drains resources that could otherwise support market expansion, thereby impeding the overall momentum of the testing services sector.

Market Trends

The growing emphasis on characterizing cell and gene therapy products is fundamentally altering the technical demands for extractable and leachable studies. Unlike conventional therapeutics, these advanced modalities frequently employ viral vectors and rely on complex single-use manifolds, requiring strict evaluation of polymeric components to avoid toxicity or immunogenicity caused by leachates. This heightened attention to material safety correlates directly with the sector's strong financial backing; the Alliance for Regenerative Medicine's "State of the Industry Briefing" in January 2025 noted that global investment in the cell and gene therapy sector hit $15.2 billion in 2024. Such substantial capital speeds up the development pipeline, forcing testing laboratories to implement specialized protocols to detect trace leachables that might jeopardize the stability of these high-value biologics.

Concurrently, the market is seeing a notable rise in E&L testing for novel drug delivery and combination products, spurred by the trend toward patient-centric self-administration devices. Combining pharmaceuticals with medical devices like pre-filled syringes, auto-injectors, and wearable pumps places new materials, such as rubber plungers and silicone oil lubricants, in direct contact with the drug, necessitating thorough interaction studies. This trend is supported by increasing delivery system production; in August 2024, Schott Pharma reported in its "Schott Pharma delivers strong third quarter results" press release that its Drug Delivery Systems segment saw a 39% year-over-year revenue increase. This swift growth in device manufacturing requires extensive extractable profiling to ensure compliance with combination product regulations, thereby maintaining demand for advanced analytical testing services.

Key Market Players

  • Eurofins Scientific SE
  • SGS SA
  • Intertek Group plc
  • WuXi AppTec
  • Merck KGaA
  • West Pharmaceutical Services, Inc.
  • Boston Analytical
  • Medical Engineering Technologies Ltd.
  • Nelson Laboratories, LLC
  • Pace Analytical Services, LLC

Report Scope

In this report, the Global Extractable & Leachable Testing Services Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Extractable & Leachable Testing Services Market, By Product Tested

  • Container Materials/ Packaging
  • Single-Use
  • Medical Devices
  • Biopharmaceuticals/ Biologicals
  • Others

Extractable & Leachable Testing Services Market, By Technique

  • Spectrometry
  • Spectroscopy
  • Total Organic Carbon
  • Conductivity
  • Others

Extractable & Leachable Testing Services Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Extractable & Leachable Testing Services Market.

Available Customizations:

Global Extractable & Leachable Testing Services Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Extractable & Leachable Testing Services Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product Tested (Container Materials/ Packaging, Single-Use, Medical Devices, Biopharmaceuticals/ Biologicals, Others)
    • 5.2.2. By Technique (Spectrometry, Spectroscopy, Total Organic Carbon, Conductivity, Others)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Extractable & Leachable Testing Services Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product Tested
    • 6.2.2. By Technique
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Extractable & Leachable Testing Services Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Product Tested
        • 6.3.1.2.2. By Technique
    • 6.3.2. Canada Extractable & Leachable Testing Services Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Product Tested
        • 6.3.2.2.2. By Technique
    • 6.3.3. Mexico Extractable & Leachable Testing Services Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Product Tested
        • 6.3.3.2.2. By Technique

7. Europe Extractable & Leachable Testing Services Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product Tested
    • 7.2.2. By Technique
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Extractable & Leachable Testing Services Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Product Tested
        • 7.3.1.2.2. By Technique
    • 7.3.2. France Extractable & Leachable Testing Services Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Product Tested
        • 7.3.2.2.2. By Technique
    • 7.3.3. United Kingdom Extractable & Leachable Testing Services Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Product Tested
        • 7.3.3.2.2. By Technique
    • 7.3.4. Italy Extractable & Leachable Testing Services Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Product Tested
        • 7.3.4.2.2. By Technique
    • 7.3.5. Spain Extractable & Leachable Testing Services Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Product Tested
        • 7.3.5.2.2. By Technique

8. Asia Pacific Extractable & Leachable Testing Services Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product Tested
    • 8.2.2. By Technique
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Extractable & Leachable Testing Services Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Product Tested
        • 8.3.1.2.2. By Technique
    • 8.3.2. India Extractable & Leachable Testing Services Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Product Tested
        • 8.3.2.2.2. By Technique
    • 8.3.3. Japan Extractable & Leachable Testing Services Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Product Tested
        • 8.3.3.2.2. By Technique
    • 8.3.4. South Korea Extractable & Leachable Testing Services Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Product Tested
        • 8.3.4.2.2. By Technique
    • 8.3.5. Australia Extractable & Leachable Testing Services Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Product Tested
        • 8.3.5.2.2. By Technique

9. Middle East & Africa Extractable & Leachable Testing Services Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product Tested
    • 9.2.2. By Technique
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Extractable & Leachable Testing Services Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Product Tested
        • 9.3.1.2.2. By Technique
    • 9.3.2. UAE Extractable & Leachable Testing Services Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Product Tested
        • 9.3.2.2.2. By Technique
    • 9.3.3. South Africa Extractable & Leachable Testing Services Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Product Tested
        • 9.3.3.2.2. By Technique

10. South America Extractable & Leachable Testing Services Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Product Tested
    • 10.2.2. By Technique
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Extractable & Leachable Testing Services Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Product Tested
        • 10.3.1.2.2. By Technique
    • 10.3.2. Colombia Extractable & Leachable Testing Services Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Product Tested
        • 10.3.2.2.2. By Technique
    • 10.3.3. Argentina Extractable & Leachable Testing Services Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Product Tested
        • 10.3.3.2.2. By Technique

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Extractable & Leachable Testing Services Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Eurofins Scientific SE
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. SGS SA
  • 15.3. Intertek Group plc
  • 15.4. WuXi AppTec
  • 15.5. Merck KGaA
  • 15.6. West Pharmaceutical Services, Inc.
  • 15.7. Boston Analytical
  • 15.8. Medical Engineering Technologies Ltd.
  • 15.9. Nelson Laboratories, LLC
  • 15.10. Pace Analytical Services, LLC

16. Strategic Recommendations

17. About Us & Disclaimer